These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16239061)

  • 21. MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.
    Zhao E; Cui D; Yuan L; Lu W
    Mol Biol Rep; 2012 Apr; 39(4):3471-7. PubMed ID: 21725850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of the
    Miedl H; Lebhard J; Ehart L; Schreiber M
    Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.
    Thunell LK; Bivik C; Wäster P; Fredrikson M; Stjernström A; Synnerstad I; Rosdahl I; Enerbäck C
    Melanoma Res; 2014 Jun; 24(3):190-7. PubMed ID: 24625390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset.
    Hamid S; Yang YH; Peng KN; Ismail SM; Zain RB; Lim KP; Wan Mustafa WM; Abraham MT; Teo SH; Cheong SC
    Oral Oncol; 2009 Jun; 45(6):496-500. PubMed ID: 18804411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Murine double-minute 2 homolog single nucleotide polymorphism 309 and the risk of gynecologic cancer.
    Ueda M; Yamamoto M; Nunobiki O; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
    Hum Cell; 2009 May; 22(2):49-54. PubMed ID: 19379464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
    Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    BMC Cancer; 2017 Feb; 17(1):97. PubMed ID: 28158999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in Singapore.
    Koh WP; Van Den Berg D; Jin A; Wang R; Yuan JM; Yu MC
    Breast Cancer Res Treat; 2011 Dec; 130(3):1011-9. PubMed ID: 21833626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
    El Hallani S; Marie Y; Idbaih A; Rodero M; Boisselier B; Laigle-Donadey F; Ducray F; Delattre JY; Sanson M
    J Neurooncol; 2007 Dec; 85(3):241-4. PubMed ID: 17568997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case-control study on the SNP309T → G and 40-bp Del1518 of the MDM2 gene and a systematic review for MDM2 polymorphisms in the patients with breast cancer.
    Jalilvand A; Yari K; Aznab M; Rahimi Z; Salahshouri Far I; Mohammadi P
    J Clin Lab Anal; 2020 Dec; 34(12):e23529. PubMed ID: 32951271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
    Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
    Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
    Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
    J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.
    Wilkening S; Hemminki K; Rudnai P; Gurzau E; Koppova K; Försti A; Kumar R
    Br J Dermatol; 2007 Aug; 157(2):375-7. PubMed ID: 17553029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
    Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MDM2 309 polymorphism is associated with missed abortion.
    Fang Y; Kong B; Yang Q; Ma D; Qu X
    Hum Reprod; 2009 Jun; 24(6):1346-9. PubMed ID: 19246469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
    Schmidt MK; Reincke S; Broeks A; Braaf LM; Hogervorst FB; Tollenaar RA; Johnson N; Fletcher O; Peto J; Tommiska J; Blomqvist C; Nevanlinna HA; Healey CS; Dunning AM; Pharoah PD; Easton DF; Dörk T; Van't Veer LJ;
    Cancer Res; 2007 Oct; 67(19):9584-90. PubMed ID: 17909070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The MDM2 309T>G polymorphism and ovarian cancer risk: a meta-analysis of 1534 cases and 2211 controls.
    Ma YY; Guan TP; Yao HB; Yu S; Chen LG; Xia YJ; He XJ; Wang HJ; Jiang XT; Tao HQ
    PLoS One; 2013; 8(1):e55019. PubMed ID: 23383041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner.
    Bond GL; Hirshfield KM; Kirchhoff T; Alexe G; Bond EE; Robins H; Bartel F; Taubert H; Wuerl P; Hait W; Toppmeyer D; Offit K; Levine AJ
    Cancer Res; 2006 May; 66(10):5104-10. PubMed ID: 16707433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No association between SNP309 promoter polymorphism in the MDM2 and cervical cancer in a study from northeastern Brazil.
    Meissner Rde V; Barbosa RN; Fernandes JV; Galvão TM; Galvão AF; Oliveira GH
    Cancer Detect Prev; 2007; 31(5):371-4. PubMed ID: 18023538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.